Abbott Pathogen Detection Platform Obtains CE Mark | GenomeWeb

NEW YORK (GenomeWeb) ― Abbott announced today that its pathogen detection platform, Iridica, has obtained CE marking and is now available in Europe and other countries that recognize the CE mark.

The diagnostic platform uses a combination of PCR and electrospray ionization mass spectrometry to amplify and detect pathogens directly from patient samples without the need for culture. It can currently distinguish over 1,000 bacteria, viruses, and fungi, according to a statement, allowing for unbiased screening of patient samples in less than six hours.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.